CPF
PDLI

Context Partners Fund’s PDL BioPharma, Inc. PDLI Stock Holding History

Context Partners Fund’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$1.47M Buy
+465,172
New +$1.49M 0.32% 79

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Context Partners Fund's PDLI Position: Q3 2020 in Review

Context Partners Fund opened a new position in PDL BioPharma, Inc. (PDLI) in Q3 2020: 465,172 shares worth $1.47M. The stake represents 0.32% of the portfolio and ranks #79 among its holdings.

132 funds tracked by Wall St. Rank hold PDLI as of Q3 2020.

  • Context Partners Fund held 465,172 shares of PDL BioPharma, Inc. worth $1.47M as of Q3 2020.
  • PDL BioPharma, Inc. was a new Context Partners Fund position in Q3 2020.
  • PDL BioPharma, Inc. made up 0.32% of Context Partners Fund's portfolio in Q3 2020, its #79 holding.
  • 132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2020.

Based on Context Partners Fund's 13F filing for Q3 2020, filed 16 Nov 2020.